Kung Chih-Han, Song Huan, Ye Weimin, Nilsson Magnus, Johansson Jan, Rouvelas Ioannis, Irino Tomoyuki, Lundell Lars, Tsai Jon A, Lindblad Mats
Department of Clinical Science, Intervention and Technology (CLINTEC), Division of Surgery, Karolinska Institutet, 171 77 Stockholm, Sweden.
Department of Surgery, Skellefteå County Hospital, 931 86 Skellefteå, Sweden.
Chin J Cancer Res. 2017 Aug;29(4):313-322. doi: 10.21147/j.issn.1000-9604.2017.04.04.
Curative gastric cancer surgery entails removal of the primary tumor with adequate margins including regional lymph nodes. European randomized controlled trials with recruitment in the 1990's reported increased morbidity and mortality for D2 compared to D1. Here, we examined the extent of lymphadenectomy during gastric cancer surgery and the associated risk for postoperative complications and mortality using the strengths of a population-based study.
A prospective nationwide study conducted within the National Register of Esophageal and Gastric Cancer. All patients in Sweden from 2006 to 2013 who underwent gastric cancer resections with curative intent were included. Patients were categorized into D0, D1, or D1+/D2, and analyzed regarding postoperative morbidity and mortality using multivariable logistic regression.
In total, 349 (31.7%) patients had a D0, 494 (44.9%) D1, and 258 (23.4%) D1+/D2 lymphadenectomy. The 30-d postoperative complication rates were 25.5%, 25.1% and 32.2% (D0, D1 and D1+/D2, respectively), and 90-d mortality rates were 8.3%, 4.3% and 5.8%. After adjustment for confounders, in multivariable analysis, there were no significant differences in risk for postoperative complications between the lymphadenectomy groups. For 90-d mortality, there was a lower risk for D1 . D0.
The majority of gastric cancer resections in Sweden have included only a limited lymphadenectomy (D0 and D1). More extensive lymphadenectomy (D1+/D2) seemed to have no impact on postoperative morbidity or mortality.
根治性胃癌手术需要切除具有足够切缘的原发性肿瘤,包括区域淋巴结。20世纪90年代开展的欧洲随机对照试验报告称,与D1手术相比,D2手术的发病率和死亡率有所增加。在此,我们利用基于人群研究的优势,研究了胃癌手术期间淋巴结清扫的范围以及术后并发症和死亡的相关风险。
在国家食管癌和胃癌登记处内进行的一项前瞻性全国性研究。纳入了2006年至2013年瑞典所有接受根治性胃癌切除术的患者。将患者分为D0、D1或D1+/D2组,并使用多变量逻辑回归分析术后发病率和死亡率。
共有349例(31.7%)患者进行了D0淋巴结清扫,494例(44.9%)进行了D1清扫,258例(23.4%)进行了D1+/D2清扫。术后30天并发症发生率分别为25.5%、25.1%和32.2%(D0、D1和D1+/D2组),90天死亡率分别为8.3%、4.3%和5.8%。在对混杂因素进行调整后,多变量分析显示,淋巴结清扫组之间术后并发症风险无显著差异。对于90天死亡率,D1组风险较低。D0组。
瑞典大多数胃癌切除术仅包括有限的淋巴结清扫(D0和D1)。更广泛的淋巴结清扫(D1+/D2)似乎对术后发病率或死亡率没有影响。